Abstract
Frailty is now defined as a clinical entity and potentially responsive to medications. This article reviews the drugs available and those under development. While, at present, exercise is the primary therapy, it is expected over the next decade that numerous drugs will be available to treat components of the frailty syndrome.
Current Pharmaceutical Design
Title: Developing Novel Therapeutic Approaches to Frailty
Volume: 15 Issue: 29
Author(s): John E. Morley
Affiliation:
Abstract: Frailty is now defined as a clinical entity and potentially responsive to medications. This article reviews the drugs available and those under development. While, at present, exercise is the primary therapy, it is expected over the next decade that numerous drugs will be available to treat components of the frailty syndrome.
Export Options
About this article
Cite this article as:
Morley E. John, Developing Novel Therapeutic Approaches to Frailty, Current Pharmaceutical Design 2009; 15 (29) . https://dx.doi.org/10.2174/138161209789105045
DOI https://dx.doi.org/10.2174/138161209789105045 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
How Moringa oleifera Supplementation Affects T-cell Subsets and Circulating Angiogenic, Myeloid, and Endothelial Cells in Mice with Alloxan-induced Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Apoptosis and Autoimmune Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry The Monocyte Locomotion Inhibitory Factor an Anti-Inflammatory Peptide; Therapeutics Originating from Amebic Abscess of the Liver
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Ex Vivo Gene Therapy and Vision
Current Gene Therapy Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Glitazones, PPAR-γ and Neuroprotection
Mini-Reviews in Medicinal Chemistry Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS
CNS & Neurological Disorders - Drug Targets Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets